Clinical Trials
35 trialsTesting the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma
National Cancer Institute (NCI)
TAPUR
American Society of Clinical Oncology
I-SPY
QuantumLeap Healthcare Collaborative
TL938 and Trastuzumab for Patients With HER2-positive Metastatic Colorectal Cancer
Suzhou Teligene Ltd.
MINUTE
Isala
H3RAKLES
Institut Curie
DETERMINE
Cancer Research UK
DETERMINE
Cancer Research UK
ATREZZO
SOLTI Breast Cancer Research Group
A Study of Evorpacept (ALX148) in Patients With Advanced Solid Tumors and Lymphoma (ASPEN-01)
ALX Oncology Inc.
ProTarget
Rigshospitalet, Denmark
My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors
Genentech, Inc.
SUMMIT
Puma Biotechnology, Inc.
DRUP
The Netherlands Cancer Institute
Safety Study of AMG 386 to Treat HER2-positive Locally Recurrent or Metastatic Breast Cancer
Amgen
Efficacy and Safety of Precision Therapy in Refractory Tumor
Shanghai Changzheng Hospital
Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR Cancers
NKGen Biotech, Inc.
A Trial of Oral BEZ235 and BKM120 in Combination With Paclitaxel With or Without Trastuzumab
Novartis
Trastuzumab in Treating Patients With Locally Advanced or Metastatic Gallbladder Cancer or Bile Duct Cancer That Cannot Be Removed by Surgery
National Cancer Institute (NCI)
Continued HER2 Suppression With Lapatinib Plus Trastuzumab Versus Trastuzumab Alone
Novartis
Study of Robatumumab (SCH 717454, MK-7454) in Combination With Different Treatment Regimens in Participants With Advanced Solid Tumors (P04722, MK-7454-004)
Merck Sharp & Dohme LLC
ZoNantax - Zolendronic Acid as Neoadjuvant Therapy Plus Anthracycline and Taxane in Locally Advanced Breast Cancer
Instituto Nacional de Cancer, Brazil
A Continuation Study of Herceptin (Trastuzumab) in Participants With Metastatic or Locally Advanced Cancer
Hoffmann-La Roche
A Study of R1507 in Combination With Multiple Standard Chemotherapy Treatments in Patients With Advanced Solid Tumors
Hoffmann-La Roche
THOR
Berufsverband Niedergelassener GynÀkologischer Onkologen in Deutschland e.V.
Bioequivalence Study Evaluating the Pharmacokinetics of DMB-3111 and Trastuzumab in Healthy Japanese Male Adults
Meiji Seika Pharma Co., Ltd.
An Open-label, Phase I/IIa, Dose Escalating Study of 2B3-101 in Patients With Solid Tumors and Brain Metastases or Recurrent Malignant Glioma.
BBB-Therapeutics B.V.
MK-2206, Paclitaxel and Trastuzumab in Treating Patients With HER2-overexpressing Solid Tumor Malignancies
University of California, San Francisco
Study of Gemcitabine and Herceptin Versus Xeloda and Herceptin in HER-2 (+) Metastatic Breast Cancer Patients
Hellenic Oncology Research Group
Trastuzumab Plus R115777 in Treating Patients With Advanced or Metastatic Cancer
National Cancer Institute (NCI)
A Pharmacokinetic Study Comparing PF-05280014 And Trastuzumab In Healthy Male Volunteers (REFLECTIONS B327-01)
Pfizer
Study With Docetaxel, Carboplatin and Herceptin Versus Vinorelbine and Herceptin in HER-2 (+) Metastatic Breast Cancer Patients
Hellenic Oncology Research Group
Safety And Efficacy Study Of The Combination Of CpG 7909 And Herceptin In Patients With Metastatic Breast Cancer
Pfizer
XRP9881 in Combination With Trastuzumab in Metastatic Breast Cancer
Sanofi
Gemcitabine, Herceptin and Radiation to Treat Cancer of the Pancreas
National Institutes of Health Clinical Center (CC)